 Sameer Nath
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 17 | 2019 | 299 | 3.020 |
Why?
| | Brain Neoplasms | 9 | 2018 | 979 | 1.240 |
Why?
| | Prostatic Neoplasms | 6 | 2019 | 921 | 1.220 |
Why?
| | Lung Neoplasms | 11 | 2019 | 2177 | 1.040 |
Why?
| | Radiotherapy, Intensity-Modulated | 7 | 2019 | 124 | 0.890 |
Why?
| | Radiation Oncology | 3 | 2021 | 75 | 0.860 |
Why?
| | Oncology Nursing | 1 | 2021 | 15 | 0.740 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2019 | 961 | 0.740 |
Why?
| | Radiation Dosage | 3 | 2019 | 132 | 0.700 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 188 | 0.690 |
Why?
| | Organs at Risk | 1 | 2019 | 30 | 0.660 |
Why?
| | Immunity, Cellular | 1 | 2019 | 248 | 0.580 |
Why?
| | Brachytherapy | 2 | 2017 | 103 | 0.560 |
Why?
| | Curriculum | 1 | 2021 | 819 | 0.480 |
Why?
| | Positron-Emission Tomography | 4 | 2018 | 259 | 0.480 |
Why?
| | Radiotherapy Dosage | 9 | 2017 | 244 | 0.480 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1355 | 0.470 |
Why?
| | Aged, 80 and over | 14 | 2019 | 6344 | 0.460 |
Why?
| | Mycosis Fungoides | 1 | 2014 | 60 | 0.450 |
Why?
| | Aged | 23 | 2019 | 19061 | 0.410 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 811 | 0.410 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2011 | 25 | 0.370 |
Why?
| | Radiography, Interventional | 1 | 2011 | 104 | 0.350 |
Why?
| | Urogenital System | 1 | 2009 | 18 | 0.340 |
Why?
| | Particle Accelerators | 1 | 2009 | 9 | 0.340 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2015 | 858 | 0.340 |
Why?
| | Middle Aged | 18 | 2019 | 26719 | 0.330 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1075 | 0.320 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1430 | 0.320 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 3039 | 0.310 |
Why?
| | Radiation Injuries | 1 | 2009 | 128 | 0.310 |
Why?
| | Follow-Up Studies | 11 | 2018 | 4411 | 0.300 |
Why?
| | Male | 24 | 2021 | 55554 | 0.300 |
Why?
| | Gastrointestinal Tract | 1 | 2009 | 169 | 0.290 |
Why?
| | Glioma | 1 | 2010 | 294 | 0.280 |
Why?
| | Adult | 15 | 2021 | 30528 | 0.270 |
Why?
| | Skin Neoplasms | 1 | 2014 | 756 | 0.270 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2018 | 77 | 0.270 |
Why?
| | Radiation Pneumonitis | 2 | 2017 | 24 | 0.270 |
Why?
| | Treatment Outcome | 10 | 2019 | 9084 | 0.240 |
Why?
| | Radiotherapy | 2 | 2017 | 176 | 0.240 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2013 | 216 | 0.230 |
Why?
| | Humans | 34 | 2021 | 114623 | 0.230 |
Why?
| | Female | 21 | 2021 | 59466 | 0.220 |
Why?
| | Cranial Irradiation | 3 | 2018 | 66 | 0.200 |
Why?
| | Retrospective Studies | 11 | 2019 | 12542 | 0.190 |
Why?
| | Multimodal Imaging | 2 | 2018 | 88 | 0.180 |
Why?
| | Radiotherapy, Computer-Assisted | 2 | 2010 | 12 | 0.180 |
Why?
| | Neoplasm Metastasis | 2 | 2019 | 522 | 0.170 |
Why?
| | Survival Analysis | 5 | 2018 | 1211 | 0.170 |
Why?
| | Brain | 2 | 2010 | 2371 | 0.170 |
Why?
| | Education, Nursing | 1 | 2021 | 79 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 193 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1121 | 0.160 |
Why?
| | Lymphopenia | 1 | 2019 | 49 | 0.160 |
Why?
| | Needs Assessment | 1 | 2021 | 314 | 0.160 |
Why?
| | Leukocyte Count | 1 | 2019 | 293 | 0.160 |
Why?
| | Neutropenia | 1 | 2019 | 125 | 0.160 |
Why?
| | Tumor Hypoxia | 1 | 2018 | 5 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 76 | 0.150 |
Why?
| | Immune System | 1 | 2019 | 172 | 0.150 |
Why?
| | Disease Progression | 3 | 2019 | 2380 | 0.150 |
Why?
| | Circulating Tumor DNA | 1 | 2018 | 22 | 0.150 |
Why?
| | Ultrasonography | 2 | 2018 | 633 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2019 | 620 | 0.150 |
Why?
| | Lymphocytes | 1 | 2019 | 330 | 0.140 |
Why?
| | Absorbable Implants | 1 | 2017 | 34 | 0.140 |
Why?
| | Neoplasm Staging | 6 | 2018 | 1167 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 577 | 0.140 |
Why?
| | Androgen Antagonists | 1 | 2017 | 69 | 0.140 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2017 | 73 | 0.140 |
Why?
| | Prognosis | 5 | 2018 | 3328 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 332 | 0.130 |
Why?
| | Antibodies | 1 | 2018 | 371 | 0.130 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 493 | 0.130 |
Why?
| | Propensity Score | 1 | 2017 | 224 | 0.130 |
Why?
| | United States | 6 | 2021 | 12176 | 0.130 |
Why?
| | Time Factors | 3 | 2018 | 6112 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 4 | 2018 | 2279 | 0.130 |
Why?
| | Heart | 1 | 2019 | 612 | 0.120 |
Why?
| | Age Factors | 2 | 2014 | 2894 | 0.120 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 304 | 0.120 |
Why?
| | Risk Factors | 4 | 2017 | 8628 | 0.120 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2018 | 127 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.120 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 179 | 0.120 |
Why?
| | Cisplatin | 2 | 2013 | 262 | 0.110 |
Why?
| | Treatment Failure | 2 | 2015 | 331 | 0.110 |
Why?
| | Young Adult | 5 | 2017 | 10455 | 0.110 |
Why?
| | Marital Status | 1 | 2014 | 41 | 0.110 |
Why?
| | Neutrophils | 1 | 2019 | 1176 | 0.110 |
Why?
| | Salvage Therapy | 2 | 2015 | 127 | 0.110 |
Why?
| | SEER Program | 1 | 2014 | 196 | 0.110 |
Why?
| | Databases, Factual | 1 | 2017 | 1124 | 0.100 |
Why?
| | Logistic Models | 1 | 2017 | 1840 | 0.100 |
Why?
| | Melanoma | 1 | 2018 | 619 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 2 | 2010 | 1177 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1040 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2011 | 45 | 0.090 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 98 | 0.090 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2009 | 25 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1767 | 0.080 |
Why?
| | Survival Rate | 4 | 2016 | 1644 | 0.080 |
Why?
| | Cause of Death | 1 | 2011 | 361 | 0.080 |
Why?
| | Prostatectomy | 1 | 2009 | 98 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4620 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2009 | 182 | 0.080 |
Why?
| | Tumor Burden | 1 | 2010 | 259 | 0.080 |
Why?
| | Postoperative Period | 1 | 2009 | 289 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1715 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2014 | 479 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2009 | 152 | 0.080 |
Why?
| | Image-Guided Biopsy | 2 | 2018 | 31 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2311 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 1 | 2011 | 510 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 275 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 2011 | 427 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2018 | 242 | 0.070 |
Why?
| | Lung | 1 | 2019 | 3558 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1448 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2097 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2537 | 0.050 |
Why?
| | Prospective Studies | 3 | 2018 | 6217 | 0.050 |
Why?
| | Physicians | 1 | 2009 | 772 | 0.050 |
Why?
| | Automation | 1 | 2020 | 73 | 0.040 |
Why?
| | Patient Positioning | 1 | 2020 | 42 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 117 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2018 | 109 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 385 | 0.040 |
Why?
| | Child, Preschool | 1 | 2010 | 9108 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 139 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.030 |
Why?
| | Risk Assessment | 2 | 2017 | 2967 | 0.030 |
Why?
| | Radiometry | 1 | 2015 | 42 | 0.030 |
Why?
| | Radiology | 1 | 2017 | 141 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 453 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 474 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1342 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1691 | 0.030 |
Why?
| | Adolescent | 1 | 2010 | 17831 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.020 |
Why?
| | Child | 1 | 2010 | 18404 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 782 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1466 | 0.020 |
Why?
| | Vinblastine | 1 | 2010 | 63 | 0.020 |
Why?
| | Motion | 1 | 2011 | 90 | 0.020 |
Why?
| | Radiographic Image Enhancement | 1 | 2010 | 52 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 135 | 0.020 |
Why?
| | Utilization Review | 1 | 2009 | 34 | 0.020 |
Why?
| | Hysterectomy | 1 | 2010 | 106 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2009 | 17 | 0.020 |
Why?
| | Fluorouracil | 1 | 2010 | 152 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 305 | 0.020 |
Why?
| | Rectum | 1 | 2010 | 153 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 4894 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2010 | 539 | 0.020 |
Why?
| | Urinary Bladder | 1 | 2010 | 162 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 508 | 0.020 |
Why?
| | Mutation | 1 | 2018 | 3344 | 0.020 |
Why?
| | Radiography | 1 | 2009 | 812 | 0.020 |
Why?
| | Data Collection | 1 | 2009 | 620 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3003 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1879 | 0.010 |
Why?
|
|
Nath's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|